Caribou Biosciences On Tuesday, the stock price closed with a bearish daily pattern, despite readings indicating oversold conditions across all three time frames. The stock closed at $1.14 that day, below the daily exponential moving average and below the lower band of the Bollinger Bands. The oversold condition complicates the bearish outlook, but it does not constitute a reversal signal.
Key Points
- The daily line RSI14 is at 27.68, which is in an oversold range; on October 5th, it was at 31.29.
- The stock price is below the 1.29 dollars of the 20-day EMA, the 1.44 dollars of the 50-day EMA, and the 1.70 dollars of the 200-day EMA.
- The lower band of the daily Bollinger Bands is at $1.14, which is consistent with the closing price of the day. On the hourly chart, RSI14 is at 26.44, and on the 15-minute chart, RSI14 is at 23.85; both are in an oversold range.
- The daily pivot point for the next trading day is $1.16, with the first resistance level at $1.19 and the first support level at $1.10.
On Tuesday, October 6, 2026, CRBU opened at $1.19, hit a low of $1.13 during the session, and closed at $1.14. Compared to the previous closing price, the daily decline was 4.62%, with a trading volume of 4,642,000 shares. The prices and technical indicators are provided by Twelve Data.
Caribou Biosciences Stock price still below the daily moving average
The daily moving averages are arranged in a bearish pattern, which supports a bearish main scenario. A bullish scenario requires not only oversold readings but also for prices to re-cross above the key upper levels.
However, on the daily chart, RSI14 dropped from 31.29 on October 5 to 27.68, entering an oversold zone. Both the daily chart MACD line and the signal line are at -0.09, and the bar chart shows a value of 0. Negative values tend to indicate a bearish trend, but at the current level of precision, there is no clear separation between the zero bar chart and the signal line.
Hourly chart confirmation: Execution conditions also indicate overselling.
The hourly chart confirms that the daily trend of CRBU is weak. The closing price is below the 20-hour EMA of $1.19, the 50-hour EMA of $1.22, and the 200-hour EMA of $1.36; all these moving averages are also arranged in a bearish pattern. The hourly RSI14 is at 26.44, indicating an oversold area; the MACD bar chart shows -0.01, indicating negative momentum.
At the same time, the closing price was above the lower band of the hourly Bollinger Bands at $1.13, but below the middle band at $1.19. The upper band is at $1.25, and the ATR14 for the hour is at $0.02. There is no disagreement in the bullish time frames here; the contradiction lies between the bearish positions and the oversold RSI readings.
15-minute execution background
From an execution perspective, the 15-minute RSI14 is at 23.85, which is also in an oversold range. The price is lower than the 1.16 USD for 20 quarter-hours EMA, 1.18 USD for 50 quarter-hours EMA, and 1.23 USD for 200 quarter-hours EMA. The 15-minute MACD bar chart shows a value of 0, indicating no confirmation of positive momentum. The lower Bollinger Band is at 1.12 USD, the middle band at 1.16 USD, and the upper band at 1.20 USD; the ATR14 is at 0.01 USD.
Post-market news
According to a report released by Yahoo Finance after the close on Tuesday, Caribou plans to evaluate strategic alternatives. The report also stated that the company intends to cease the vispa-cel and CB-011 variants of the CAR-T cell therapy projects. A report released by Investing.com after the same close also mentioned strategic alternatives and the suspension of the CAR-T project.
Subsequently, a report published on Wednesday, October 7th by Investing.com, stated that RBC Capital downgraded its rating on Caribou Biosciences's stock due to a strategic review. This report pertains to the following day's content and does not relate to the trading period of Tuesday.
Call and put conditions for the next trading day
The daily pivot point for the next trading day is at $1.16, with the first resistance level at $1.19 and the first support level at $1.10. These levels are based on the previous complete daily candlestick chart and are applicable when trading resumes.
A bullish scenario requires the price to hold above the daily low of $1.13 and to re-establish itself above the $1.16 daily pivot point. If it further breaks through the first resistance level of $1.19, this scenario will be strengthened. The next set of daily reference levels are the middle band of the Bollinger Bands at $1.27 and the 20-day EMA at $1.29. A return above $30 for RSI14 would cancel out the oversold condition on the daily chart, but it does not necessarily mean that an upward trend has been formed.
On the contrary, if it falls below the daily low of $1.13, it will weaken the aforementioned bullish scenario. If it further breaks below the first support level of $1.10 on the daily chart, it will reinforce the bearish scenario. As long as it remains below the daily pivot point of $1.16, the recent upper resistance has not yet been overcome.
Overall, CRBU is trading at $1.14, below the lower band of the daily Bollinger Bands and also below the three-day moving averages. The daily ATR14 is at $0.06, while the hourly and 15-minute readings are $0.02 and $0.01 respectively. The bearish pattern is quite clear; however, it is still uncertain whether the oversold condition will lead to a recovery towards the upper resistance levels.
Frequently Asked Questions
Caribou Biosciences What is the technical structure of stocks?
CRBU closed at $1.14 on Tuesday, lower than the $1.29 on the 20-day EMA, $1.44 on the 50-day EMA, and $1.70 on the 200-day EMA. The daily RSI14 indicator is at 27.68, indicating an oversold condition, while the daily MACD bar chart shows a value of 0.
CRBU What key price levels need to be watched?
The daily pivot point for the next trading day is $1.16. The first resistance level is at $1.19, and the first support level is at $1.10. The lower band of the daily Bollinger Bands, which is at $1.14, coincides with the closing price on Tuesday. Above that is the middle band of the Bollinger Bands at $1.27, and the 20-day EMA level of $1.29, which constitute the next set of upper reference points.
What news was released about Caribou Biosciences after the market closed?
A report released after the close on Tuesday by Yahoo Finance stated that the company plans to evaluate strategic alternatives and will cease the vispa-cel and CB-011 variants of the CAR-T cell therapy projects. A report published on Wednesday, October 7th, by Investing.com indicated that RBC Capital downgraded its rating on Caribou Biosciences shares due to a strategic review.
Cryptonomist and the author do not hold any positions in the financial instruments mentioned in this text, nor have they received any compensation from the companies reported.
This article was generated with the assistance of artificial intelligence and has been reviewed by an editorial team.
